TuHURA Biosciences, Inc./NV

Company snapshot

TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for TuHURA Biosciences, Inc./NV. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for TuHURA Biosciences, Inc./NV.

1. May 23, 2026 Clinical update

   IFx-Hu2.0 — Phase 3

2. May 23, 2026 Clinical update

   IFx-Hu2.0 — Phase 1

3. May 23, 2026 Clinical update

   IFx-Hu2.0 — Phase 1

4. May 23, 2026 Clinical update

   IFx-Hu2.0 — Phase 1

View all clinical trial activity →

• What is TuHURA Biosciences, Inc./NV?

  TuHURA Biosciences is a pharma organization headquartered in Tampa, USA. It trades on NYSE under ticker HURA. Primary therapeutic focus areas include Advanced Or Metastatic Merkel Cell Carcinoma, Cutaneous Melanoma, Stage III, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcin

• Is TuHURA Biosciences, Inc./NV publicly traded?

  Yes. TuHURA Biosciences, Inc./NV is listed with ticker HURA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does TuHURA Biosciences, Inc./NV develop or market?

  No drug profiles are currently linked to TuHURA Biosciences, Inc./NV. Pipeline programs may still list investigational assets.

• What are the latest developments for TuHURA Biosciences, Inc./NV?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does TuHURA Biosciences, Inc./NV focus on?

  TuHURA Biosciences, Inc./NV focuses on Advanced Or Metastatic Merkel Cell Carcinoma, Cutaneous Melanoma, Stage III, Cutaneous Squamous Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.